This report provides a comprehensive analysis of the global cardiovascular devices market, examining its growth trajectory driven by the rising prevalence of cardiovascular diseases and advancements in minimally invasive technologies. The study explores key segments, including the dominant coronary artery disease category and the rapidly expanding cardiac imaging and diagnostic device sector. Furthermore, it highlights the increasing demand for remote monitoring and the significant growth potential within the Asia-Pacific region. Through competitive assessments and technological trend analysis, the report offers vital strategic insights for industry stakeholders.

Market Overview

The global cardiovascular devices market is valued at USD 77.71 billion in 2024 and is projected to reach USD 110.39 billion by 2029, growing at a CAGR of 7.3% during the forecast period.

Growth Drivers & Trends

The expansion of the cardiovascular devices market is propelled by several critical factors:

• Increasing Prevalence of Cardiovascular Diseases (CVD): As global rates of heart disease rise, there is a heightened need for effective monitoring and treatments such as angioplasty, stenting, and valve replacements.
• Advancements in Minimally Invasive Procedures: Technological innovations are enabling safer and more precise medical interventions.
• Technological Innovations: The development of drug-eluting stents, bioresorbable scaffolds, occluders, and advanced imaging technologies contributes significantly to market growth.
• Demand for Improved Patient Outcomes: A growing focus on clinical efficacy and patient recovery.
• Shifting Preference to Remote Monitoring: Increasing reliance on technology to manage patient health outside of traditional clinical settings.

Market Segmentation

By Product Type

• Cardiac Imaging and Diagnostic Devices: This segment holds a significant share of the cardiovascular devices market and is expected to grow at the highest rate. These technologies visualize the heart and assess functions to enable detection, diagnosis, and monitoring of heart diseases by providing detailed images of heart structure, blood flow, and electrical activity.
• Growth Drivers for this Segment: Growing global CVD burden, advancing imaging technologies, rising importance of early diagnosis, and the rise of precision medicine.
• Technological Drivers: Advancements such as real-time 3D echocardiography, cardiac MRI, and AI-assisted imaging solutions enhance diagnostic efficiency and quality of care.
• Additional Factors: Prevalence of chronic diseases, government initiatives, healthcare reimbursement policies in advanced and emerging markets, and the accessibility provided by telehealth and portable diagnostic devices.
• Coronary Artery Disease (CAD) Segment: This segment holds the largest market share in the cardiovascular devices market.
• Condition Overview: CAD occurs when plaque (atherosclerosis) builds up inside the coronary arteries, narrowing or blocking blood flow to the heart muscle. This can result in breathlessness, angina, or extreme cases such as myocardial infarction (heart attack).
• Contributing Factors: Unhealthy lifestyles (diet high in saturated fats, lack of exercise, smoking), hypertension, high cholesterol, diabetes, obesity, genetic disposition, age, and chronic stress.
• Market Impact: The increasing incidence of these risk factors, coupled with heightened population awareness, is aiding market growth.

By End User

• Others Segment: This segment is expected to grow by a significant CAGR, representing the fastest-growing area in the market. It includes applications such as:
• General health checkups, fitness, and wellness monitoring.
• Intraoperative monitoring.
• Post-operative care.
• Growth Drivers: Increased focus on preventive care, personalized medicine, and holistic patient care. There is growing demand for wearable and connected devices (measuring heart rate, blood pressure, and ECG) among both healthy and chronic disease patients.
• Clinical Applications: Advanced intraoperative equipment improves real-time surgical safety and patient comfort, while post-surgery monitoring aids in recovery tracking, early complication detection, and minimizing hospital readmission.
• Technological Integration: The integration of AI and IoT improves data accuracy and clinician decision-making, while telehealth and remote monitoring allow for continued care outside clinical settings.

Regional Analysis

Asia Pacific

The Asia-Pacific region is expected to grow with the highest CAGR during the forecast period. Key drivers include:

• An increasingly aging population.
• Growing prevalence of cardiovascular diseases.
• Increased adoption of minimally invasive procedures, particularly in China, Japan, and India.
• Increased healthcare spending and the development of health infrastructure, promoting high-end interventional cardiology services.

Competitive Landscape

Primary Participant Profiles

By Company Type:

• Tier 1: 35%
• Tier 2: 45%
• Tier 3: 20%

By Designation:

• C-level Executives: 35%
• Directors: 25%
• Others: 40%

By Region:

• North America: 40%
• Europe: 30%
• APAC: 20%
• Latin America: 5%
• Middle East & Africa: 5%

Key Players

• Abbott Laboratories (US)
• AngioDynamics, Inc. (US)
• Artivion Inc (US)
• Baxter International Inc (US)
• Biotronik (Germany)
• B. Braun SE (Germany)
• BPL Medical Technologies (India)
• Boston Scientific Corporation (US)
• Canon Medical Systems Corporation (Japan)
• Edward Lifesciences Corporation (US)
• GE Healthcare Technologies, Inc. (US)
• Getinge AB (Sweden)
• Johnson & Johnson (US)
• Koninklijke Philips N.V. (Netherlands)
• Lepu Medical Technology (Beijing) Co., Ltd (China)
• LifeTech Scientific Corporation (China)
• Medtronic Plc (Ireland)
• MicroPort Scientific Corporation (China)
• Nihon Kohden Corporation (Japan)
• OrbusNeich Medical Group Holdings Limited (China)
• Picard Medical Company (US)
• Sahajanand Medical Technologies Limited (India)
• Siemens Healthineers AG (Germany)
• Terumo Corporation (Japan)
• W.L. Gore & Associates, Inc (US)
• Japan Lifeline Co., Ltd. (Japan)

Research Coverage & Report Insights

Scope of Analysis

The report estimates market size and future growth potential across various segments including products, indications, and end users. It includes a product portfolio matrix of available technologies and a competitive analysis featuring company profiles, product offerings, and key market strategies.

Strategic Value (Reasons to Buy)

• For Market Leaders & New Entrants: Provides close approximations of revenue numbers for the overall market and subsegments to assist in positioning and go-to-market strategies.
• For Stakeholders: Offers insights into the market pulse, including drivers, restraints, challenges, and opportunities.

Detailed Analytical Pointers

• Market Dynamics:
• Drivers: Increase in CVD prevalence, preference for minimally invasive techniques, technological innovation, and the rise of remote patient monitoring.
• Restraints: Stringent regulatory guidelines for product approval and a lack of skilled cardiovascular healthcare professionals.
• Opportunities: Projected growth in the elderly population and emerging opportunities in biodegradable cardiovascular devices.
• Challenges: Product failures, recalls, and adverse effects or complications associated with implantable devices.
• Product Innovation & Development: Comprehensive details on new product launches, anticipated trends, upcoming research and development activities, and R&D trends.
• Market Development & Diversification: Information on lucrative emerging markets (by product, indication, and end user), product enhancements, growing geographies, recent developments, and investments.
• Competitive Assessment: Thorough evaluation of market shares, growth plans, product/service offerings, and capacities of major competitors.

• 2 RESEARCH METHODOLOGY 38

  • 2.1 RESEARCH DATA 38

    • 2.1.1 SECONDARY DATA 39

      • 2.1.1.1 Key data from secondary sources 40

    • 2.1.2 PRIMARY DATA 40

      • 2.1.2.1 Key data from primary sources 42
      • 2.1.2.2 Key industry insights 42

  • 2.2 MARKET SIZE ESTIMATION 43

  • 2.3 GROWTH FORECAST 45

  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION 48

  • 2.5 MARKET RANKING ANALYSIS 49

  • 2.6 STUDY ASSUMPTIONS 49

  • 2.7 RESEARCH LIMITATIONS 49

    • 2.7.1 METHODOLOGY-RELATED LIMITATIONS 49

    • 2.7.2 SCOPE-RELATED LIMITATIONS 50

  • 2.8 RISK ASSESSMENT 50

• 3 EXECUTIVE SUMMARY 51

• 4 PREMIUM INSIGHTS 55

  • 4.1 CARDIOVASCULAR DEVICES MARKET OVERVIEW 55

  • 4.2 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET

  • 4.3 CARDIOVASCULAR DEVICES MARKET: REGIONAL MIX, 2024-2029 (USD MILLION) 57

• 5 MARKET OVERVIEW 58

  • 5.1 INTRODUCTION 58

  • 5.2 MARKET DYNAMICS 58

    • 5.2.1 DRIVERS 59

      • 5.2.1.1 Rising incidence of cardiovascular diseases 59
      • 5.2.1.2 Increasing accessibility to advanced high-performance devices 59
      • 5.2.1.3 Growing preference for minimally invasive surgeries 60
      • 5.2.1.4 Rising technological advancements in cardiovascular devices 60
      • 5.2.1.5 Increasing trend of remote patient monitoring 60

    • 5.2.2 RESTRAINTS 61

      • 5.2.2.1 Stringent regulatory guidelines for product approval 61
      • 5.2.2.2 Shortage of skilled cardiac health professionals 62

    • 5.2.3 OPPORTUNITIES 62

      • 5.2.3.1 Rising geriatric population and increasing uptake of CVD devices 62
      • 5.2.3.2 Emergence of biodegradable cardiovascular devices 62

    • 5.2.4 CHALLENGES 63

      • 5.2.4.1 Product recalls & failures 63
      • 5.2.4.2 Complications associated with implantable devices 63

  • 5.3 INDUSTRY TRENDS 64

    • 5.3.1 MINIMALLY INVASIVE PROCEDURES 65

    • 5.3.2 WEARABLE TECHNOLOGY AND REMOTE MONITORING 65

    • 5.3.3 PERSONALIZED MEDICINE 65

  • 5.4 TECHNOLOGY ANALYSIS 66

    • 5.4.1 KEY TECHNOLOGIES 66

      • 5.4.1.1 Transcatheter aortic valve replacement (TAVR) 66
      • 5.4.1.2 Cardiac mapping systems 66
      • 5.4.1.3 3D-printed cardiovascular devices 67

    • 5.4.2 COMPLEMENTARY TECHNOLOGIES 67

      • 5.4.2.1 Robotic-assisted surgeries 67
      • 5.4.2.2 Advanced catheter systems 67
      • 5.4.2.3 Imaging technologies 68

    • 5.4.3 ADJACENT TECHNOLOGIES 68

      • 5.4.3.1 Regenerative medicine 68
      • 5.4.3.2 Biomaterials & nanotechnology 68
      • 5.4.3.3 Big data & cloud computing 69

  • 5.5 PORTER’S FIVE FORCE ANALYSIS 69

    • 5.5.1 THREAT OF NEW ENTRANTS 69

    • 5.5.2 BARGAINING POWER OF SUPPLIERS 70

    • 5.5.3 BARGAINING POWER OF BUYERS 70

    • 5.5.4 THREAT OF SUBSTITUTES 70

    • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY 70

  • 5.6 REGULATORY LANDSCAPE 71

    • 5.6.1 REGULATORY ANALYSIS 71

      • 5.6.1.1 North America 71
        • 5.6.1.1.1 US 71
        • 5.6.1.1.2 Canada 72
      • 5.6.1.2 Europe 72
      • 5.6.1.3 Asia Pacific 72
      • 5.6.1.4 Latin America 73
      • 5.6.1.5 Middle East & Africa 73

    • 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74

  • 5.7 PATENT ANALYSIS 76

    • 5.7.1 PATENT PUBLICATION TRENDS IN CARDIOVASCULAR DEVICES MARKET 76

    • 5.7.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 77

  • 5.8 TRADE ANALYSIS 80

  • 5.9 PRICING ANALYSIS 80

  • 5.10 KEY CONFERENCES & EVENTS, 2024-2025 82

  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 83

    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 83

    • 5.11.2 BUYING CRITERIA 84

  • 5.12 UNMET NEEDS/END-USER EXPECTATIONS IN CARDIOVASCULAR DEVICES MARKET 85

  • 5.13 IMPACT OF AI/GENERATIVE AI ON CARDIOVASCULAR DEVICES MARKET 86

  • 5.14 ECOSYSTEM ANALYSIS 86

  • 5.15 CASE STUDY ANALYSIS 88

    • 5.15.1 CASE STUDY 1: EVALUATION OF TAVR SYSTEM 88

    • 5.15.2 CASE STUDY 2: SAFETY & EFFICACY ASSESSMENT OF WATCHMAN DEVICE IN ATRIAL FIBRILLATION 89

    • 5.15.3 CASE STUDY 3: PERFORMANCE ANALYSIS OF MITRACLIP FOR THE TREATMENT OF MITRAL REGURGITATION 90

  • 5.16 SUPPLY CHAIN ANALYSIS 90

  • 5.17 ADJACENT MARKET ANALYSIS 92

    • 5.17.1 CARDIAC MONITORING AND RHYTHM MANAGEMENT DEVICES MARKET 92

  • 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 93

  • 5.19 CARDIOVASCULAR DEVICES MARKET: INVESTMENT & FUNDING SCENARIO 94

  • 5.20 R&D PIPELINE ANALYSIS 95

• 6 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT 96

  • 6.1 INTRODUCTION 97

  • 6.2 CARDIAC IMAGING & DIAGNOSTIC DEVICES 98

    • 6.2.1 ECG DEVICES 100

      • 6.2.1.1 Low costs and expanding applications to fuel market 100

    • 6.2.2 CARDIAC ULTRASOUND IMAGING 101

      • 6.2.2.1 Growing preference towards minimally invasive techniques to boost demand 101

    • 6.2.3 CARDIAC COMPUTERIZED TOMOGRAPHY (CT) SCANNERS 103

      • 6.2.3.1 Increasing preference over other diagnostic imaging methods to drive market 103

    • 6.2.4 CARDIAC MAGNETIC RESONANCE IMAGING (MRI) 104

      • 6.2.4.1 Increasing incidence of cardiac diseases to fuel uptake 104

    • 6.2.5 NUCLEAR CARDIOLOGY SYSTEMS 106

      • 6.2.5.1 Ability to assess tissue functionality and heart physiology to support market growth 106

    • 6.2.6 CARDIAC DIAGNOSTIC CATHETERS 107

      • 6.2.6.1 Rising focus on catheterization procedures to fuel market 107

  • 6.3 CARDIAC RHYTHM MANAGEMENT DEVICES 109

    • 6.3.1 PACEMAKERS 111

      • 6.3.1.1 Growing availability of leadless and MRI-safe devices to boost demand 111

    • 6.3.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD) 112

      • 6.3.2.1 Increasing prevalence of arrhythmias to drive market 112

    • 6.3.3 CARDIAC RESYNCHRONIZATION THERAPY (CRT) DEVICES 114

      • 6.3.3.1 Ability to reduce fatigue and associated heart failure symptoms to boost demand 114

  • 6.4 INTERVENTIONAL CARDIOLOGY DEVICES 115

    • 6.4.1 CORONARY STENTS 118

      • 6.4.1.1 Technological advancements in stents to fuel uptake 118

    • 6.4.2 HEART VALVE DEVICES 120

      • 6.4.2.1 Increasing prevalence of valve stenosis and regurgitation to fuel market 120

    • 6.4.3 CLOSURE DEVICES 121

      • 6.4.3.1 Utilization of self-expandable materials to drive market 121

    • 6.4.4 SURGICAL CATHETERS 122

      • 6.4.4.1 Rising adoption of angioplasty procedures to support market growth 122

    • 6.4.5 GUIDEWIRES 124

      • 6.4.5.1 Rising uptake in PCI procedures to drive market 124

    • 6.4.6 OTHER INTERVENTIONAL CARDIOLOGY DEVICES 125

  • 6.5 CARDIAC ASSIST DEVICES 127

    • 6.5.1 VENTRICULAR ASSIST DEVICES 129

      • 6.5.1.1 Rising incidence of heart failure to boost market 129

    • 6.5.2 INTRA-AORTIC BALLOON PUMPS (IABP) 130

      • 6.5.2.1 Product recalls to restrain market 130

    • 6.5.3 TOTAL ARTIFICIAL HEART (TAH) 131

      • 6.5.3.1 Growing product pipeline to fuel market 131

    • 6.5.4 IMPELLA DEVICES 133

      • 6.5.4.1 Increasing utility in high-risk procedures to support market growth 133

  • 6.6 ELECTROPHYSIOLOGY DEVICES 134

    • 6.6.1 EP CATHETERS 136

      • 6.6.1.1 Rising incidence of chronic heart conditions to drive market 136

    • 6.6.2 ABLATION SYSTEMS 137

      • 6.6.2.1 Increasing utilization of radiofrequency ablation procedures to support market growth 137

    • 6.6.3 3D MAPPING SYSTEM 139

      • 6.6.3.1 Development of alternative technologies to hinder market 139

  • 6.7 EXTERNAL SUPPORT DEVICES 140

    • 6.7.1 EXTERNAL DEFIBRILLATORS 142

      • 6.7.1.1 Adoption of user-friendly AEDs to fuel market 142

    • 6.7.2 EXTERNAL PACEMAKERS 143

      • 6.7.2.1 Technological advancements in leadless & implantable pacemakers to restrain market 143

    • 6.7.3 CARDIAC COMPRESSION DEVICES 145

      • 6.7.3.1 Reduced CPR rate to restrain market 145

  • 6.8 MONITORING DEVICES 146

    • 6.8.1 BLOOD PRESSURE MONITORS 148

      • 6.8.1.1 Portability and ease of use to fuel market 148

    • 6.8.2 PULSE OXIMETERS 149

      • 6.8.2.1 Increasing adoption of OTC devices in home care settings to propel market 149

    • 6.8.3 IMPLANTABLE CARDIAC MONITORS (ICM) 151

      • 6.8.3.1 Growing focus on RPM to support market 151

• 7 CARDIOVASCULAR DEVICES MARKET, BY INDICATION 153

  • 7.1 INTRODUCTION 154

  • 7.2 CORONARY ARTERY DISEASE 155

    • 7.2.1 ANGINA PECTORIS 156

      • 7.2.1.1 Growing adoption of implantable monitors and ECG devices for treatment to drive market 156

    • 7.2.2 MYOCARDIAL INFARCTION 158

      • 7.2.2.1 Increasing demand for stents in acute cases to fuel market 158

  • 7.3 ARRHYTHMIAS 159

    • 7.3.1 TACHYCARDIA 161

      • 7.3.1.1 Rising cardiac electrophysiology procedures to drive market 161

    • 7.3.2 BRADYCARDIA 162

      • 7.3.2.1 Rising incidence of OSA to support market growth 162

  • 7.4 STRUCTURAL HEART DISEASE 164

    • 7.4.1 VALVULAR HEART DISEASE 165

      • 7.4.1.1 Rising risks of aortic stenosis to drive market 165

    • 7.4.2 CONGENITAL HEART DISEASE 167

      • 7.4.2.1 Potential for new therapies to fuel uptake 167

    • 7.4.3 CARDIOMYOPATHY 168

      • 7.4.3.1 Uptake of ICDs to drive market 168

    • 7.4.4 CONGESTIVE HEART FAILURE 170

      • 7.4.4.1 Growth in geriatric population to fuel market 170

  • 7.5 INFLAMMATORY HEART DISEASE 171

    • 7.5.1 PERICARDITIS 173

      • 7.5.1.1 Increasing incidence due to COVID-19 to support market growth 173

    • 7.5.2 MYOCARDITIS 175

      • 7.5.2.1 Increasing prevalence of autoimmune diseases to support market growth 175

    • 7.5.3 ENDOCARDITIS 176

      • 7.5.3.1 Focus on echocardiography for clinical evaluation to drive market 176

  • 7.6 OTHER CARDIOVASCULAR INDICATIONS 178

• 8 CARDIOVASCULAR DEVICES MARKET, BY END USER 180

  • 8.1 INTRODUCTION 181

  • 8.2 HOSPITALS & CLINCS 182

    • 8.2.1 HIGH PURCHASING POWER OF HOSPITALS AND RISING NUMBER OF CARDIOVASCULAR PROCEDURES TO DRIVE MARKET 182

  • 8.3 DIAGNOSTIC LABORATORIES 184

    • 8.3.1 RISING FOCUS ON TECHNOLOGICALLY ADVANCED DIAGNOSTIC INSTRUMENTS TO SUPPORT MARKET GROWTH 184

  • 8.4 AMBULATORY SURGERY CENTERS 185

    • 8.4.1 INCREASING DEMAND FOR OUTPATIENT CARE AND RPM SERVICES TO PROPEL MARKET 185

  • 8.5 OTHER END USERS 187

• 9 CARDIOVASCULAR DEVICES MARKET, BY REGION 189

  • 9.1 INTRODUCTION 190

  • 9.2 NORTH AMERICA 191

    • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 191

    • 9.2.2 US 205

      • 9.2.2.1 Increasing cases of obesity due to sedentary lifestyles to propel market 205

    • 9.2.3 CANADA 216

      • 9.2.3.1 Increasing funding for CVD research to support market growth 216

  • 9.3 EUROPE 227

    • 9.3.1 INCREASING PRODUCT APPROVALS FOR ADVANCED CARDIOVASCULAR DEVICES TO DRIVE MARKET 227

    • 9.3.2 MACROECONOMIC OUTLOOK FOR EUROPE 227

  • 9.4 ASIA PACIFIC 240

    • 9.4.1 LARGE TARGET PATIENT POPULATION AND INCREASING INCIDENCE OF CVD TO PROPEL MARKET 240

    • 9.4.2 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 240

  • 9.5 LATIN AMERICA 252

    • 9.5.1 BURDEN OF CONGENITAL HEART DISEASES TO DRIVE MARKET 252

    • 9.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 253

  • 9.6 MIDDLE EAST & AFRICA 265

    • 9.6.1 RISING HEALTHCARE EXPENDITURE TO SUPPORT MARKET GROWTH 265

    • 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 265

• 10 COMPETITIVE LANDSCAPE 279

  • 10.1 OVERVIEW 279

  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 279

    • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CARDIOVASCULAR DEVICES MARKET 280

  • 10.3 REVENUE ANALYSIS 282

  • 10.4 MARKET SHARE ANALYSIS 283

    • 10.4.1 RANKING OF KEY MARKET PLAYERS, 2023 285

  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 285

    • 10.5.1 STARS 285

    • 10.5.2 EMERGING LEADERS 285

    • 10.5.3 PERVASIVE PLAYERS 286

    • 10.5.4 PARTICIPANTS 286

    • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 287

      • 10.5.5.1 Company footprint 287
      • 10.5.5.2 Region footprint 288
      • 10.5.5.3 Product footprint 289
      • 10.5.5.4 Indication footprint 290
      • 10.5.5.5 End-user footprint 291

  • 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 292

    • 10.6.1 PROGRESSIVE COMPANIES 292

    • 10.6.2 RESPONSIVE COMPANIES 292

    • 10.6.3 DYNAMIC COMPANIES 292

    • 10.6.4 STARTING BLOCKS 292

    • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 294

  • 10.7 COMPANY VALUATION & FINANCIAL METRICS 295

    • 10.7.1 COMPANY VALUATION 295

    • 10.7.2 FINANCIAL METRICS 296

  • 10.8 BRAND/PRODUCT COMPARISON 296

  • 10.9 COMPETITIVE SCENARIO 297

    • 10.9.1 PRODUCT LAUNCHES & APPROVALS 297

    • 10.9.2 DEALS 298

    • 10.9.3 EXPANSIONS 299

    • 10.9.4 OTHER DEVELOPMENTS 299

• 11 COMPANY PROFILES 300

  • 11.1 KEY PLAYERS 300

    • 11.1.1 MEDTRONIC 300

      • 11.1.1.1 Business overview 300
      • 11.1.1.2 Products offered 301
      • 11.1.1.3 Recent developments 309
        • 11.1.1.3.1 Product launches & approvals 309
        • 11.1.1.3.2 Deals 310
      • 11.1.1.4 MnM view 311
        • 11.1.1.4.1 Key strengths 311
        • 11.1.1.4.2 Strategic choices 311
        • 11.1.1.4.3 Weaknesses & competitive threats 311

    • 11.1.2 ABBOTT LABORATORIES 312

      • 11.1.2.1 Business overview 312
      • 11.1.2.2 Products offered 313
      • 11.1.2.3 Recent developments 321
        • 11.1.2.3.1 Product launches & approvals 321
        • 11.1.2.3.2 Deals 323
      • 11.1.2.4 MnM view 323
        • 11.1.2.4.1 Key strengths 323
        • 11.1.2.4.2 Strategic choices 324
        • 11.1.2.4.3 Weaknesses & competitive threats 324

    • 11.1.3 BOSTON SCIENTIFIC CORPORATION 325

      • 11.1.3.1 Business overview 325
      • 11.1.3.2 Products offered 326
      • 11.1.3.3 Recent developments 333
        • 11.1.3.3.1 Product launches & approvals 333
        • 11.1.3.3.2 Deals 333
      • 11.1.3.4 MnM view 335
        • 11.1.3.4.1 Key strengths 335
        • 11.1.3.4.2 Strategic choices 335
        • 11.1.3.4.3 Weaknesses & competitive threats 335

    • 11.1.4 GE HEALTHCARE 336

      • 11.1.4.1 Business overview 336
      • 11.1.4.2 Products offered 337
      • 11.1.4.3 Recent developments 339
        • 11.1.4.3.1 Product launches & approvals 339
        • 11.1.4.3.2 Deals 340
      • 11.1.4.4 MnM view 341
        • 11.1.4.4.1 Key strengths 341
        • 11.1.4.4.2 Strategic choices 341
        • 11.1.4.4.3 Weaknesses & competitive threats 341

    • 11.1.5 TERUMO CORPORATION 342

      • 11.1.5.1 Business overview 342
      • 11.1.5.2 Products offered 343
      • 11.1.5.3 Recent developments 347
        • 11.1.5.3.1 Product launches & approvals 347
      • 11.1.5.4 MnM view 348
        • 11.1.5.4.1 Key strengths 348
        • 11.1.5.4.2 Strategic choices 348
        • 11.1.5.4.3 Weaknesses & competitive threats 348

    • 11.1.6 EDWARDS LIFESCIENCES CORPORATION 349

      • 11.1.6.1 Business overview 349
      • 11.1.6.2 Products offered 350
      • 11.1.6.3 Recent developments 352
        • 11.1.6.3.1 Product launches & approvals 352
        • 11.1.6.3.2 Deals 353

    • 11.1.7 SIEMENS HEALTHINEERS AG 354

      • 11.1.7.1 Business overview 354
      • 11.1.7.2 Products offered 355
      • 11.1.7.3 Recent developments 357
        • 11.1.7.3.1 Product launches & approvals 357

    • 11.1.8 JOHNSON AND JOHNSON SERVICES, INC 358

      • 11.1.8.1 Business overview 358
      • 11.1.8.2 Products offered 359
      • 11.1.8.3 Recent developments 362
        • 11.1.8.3.1 Product launches & approvals 362
        • 11.1.8.3.2 Deals 363

    • 11.1.9 SAHAJANAND MEDICAL TECHNOLOGIES LIMITED 364

      • 11.1.9.1 Business overview 364
      • 11.1.9.2 Products offered 364

    • 11.1.10 BAXTER INTERNATIONAL INC 366

      • 11.1.10.1 Business overview 366
      • 11.1.10.2 Products offered 367
      • 11.1.10.3 Recent developments 369
        • 11.1.10.3.1 Deals 369

    • 11.1.11 ARTIVION, INC 370

      • 11.1.11.1 Business overview 370
      • 11.1.11.2 Products offered 371

    • 11.1.12 GETINGE AB 373

      • 11.1.12.1 Business overview 373
      • 11.1.12.2 Products offered 374
      • 11.1.12.3 Recent developments 375
        • 11.1.12.3.1 Product launches & approvals 375
        • 11.1.12.3.2 Deals 375

    • 11.1.13 KONINKLIJKE PHILIPS N.V 376

      • 11.1.13.1 Business overview 376
      • 11.1.13.2 Products offered 377
      • 11.1.13.3 Recent developments 379
        • 11.1.13.3.1 Product launches & approvals 379

    • 11.1.14 NIHON KOHDEN CORPORATION 380

      • 11.1.14.1 Business overview 380
      • 11.1.14.2 Products offered 381

    • 11.1.15 BIOTRONIK SE & CO.KG 383

      • 11.1.15.1 Business overview 383
      • 11.1.15.2 Products offered 383

    • 11.1.16 LEPU MEDICAL TECHNOLOGY(BEIJING) CO., LTD 388

      • 11.1.16.1 Business overview 388
      • 11.1.16.2 Products offered 388
      • 11.1.16.3 Recent developments 394
        • 11.1.16.3.1 Product launches & approvals 394

    • 11.1.17 MICROPORT SCIENTIFIC CORPORATION 396

      • 11.1.17.1 Business overview 396
      • 11.1.17.2 Products offered 397
      • 11.1.17.3 Recent developments 401
        • 11.1.17.3.1 Product launches & approvals 401

    • 11.1.18 ANGIODYNAMICS INC 403

      • 11.1.18.1 Business overview 403
      • 11.1.18.2 Products offered 405

    • 11.1.19 JAPAN LIFELINE CO., LTD 406

      • 11.1.19.1 Business overview 406
      • 11.1.19.2 Products offered 407
      • 11.1.19.3 Recent developments 410
        • 11.1.19.3.1 Product launches & approvals 410

    • 11.1.20 W.L. GORE & ASSOCIATES 411

      • 11.1.20.1 Business overview 411
      • 11.1.20.2 Products offered 411

    • 11.1.21 B. BRAUN SE 412

      • 11.1.21.1 Business overview 412
      • 11.1.21.2 Products offered 414

  • 11.2 OTHER PLAYERS 415

    • 11.2.1 CANON MEDICAL SYSTEMS CORPORATION 415

    • 11.2.2 PICARD MEDICAL COMPANY 416

    • 11.2.3 BPL MEDICAL TECHNOLOGIES PVT LTD 417

    • 11.2.4 LIFETECH SCIENTIFIC CORPORATION 418

    • 11.2.5 ORBUSNEICH MEDICAL GROUP HOLDINGS LIMITED 419

• 12 APPENDIX 420

  • 12.1 DISCUSSION GUIDE 420

  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 425

  • 12.3 CUSTOMIZATION OPTIONS 427

  • 12.4 RELATED REPORTS 427

  • 12.5 AUTHOR DETAILS 428